Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy

Antiviral Therapy

Volumn 8, Issue 2, 2003, Pages 91-96

  Brumme, Zabrina L ^a   Chan, Keith J ^a   Dong, Winnie W Y ^a   Wynhoven, Brian ^a   Mo, Theresa ^a   Hogg, Robert S ^a   Montaner, Julio S G ^a,b   O'Shaughnessy, Michael V ^a,b   Harrigan, P Richard ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD6 ANTIGEN; GAG PROTEIN; NUCLEOSIDE DERIVATIVE; P6 GAG PROTEIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE INSERTION; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS ENVELOPE; VIRUS GENE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BRITISH COLUMBIA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, GAG; GENOTYPE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTAGENESIS, INSERTIONAL; PEPTIDE FRAGMENTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 0038664395     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L & Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. Journal of Virology 1996; 70:3763-3769.
2. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB & Salzman NP. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. Journal of Virology 1997; 71:6662-6670.
3. Peters S, Munoz M, Yerly S, Sanchez-Merino V, Lopez-Galindez C, Perrin L, Larder B, Cmarko D, Fakan S, Meylan P & Telenti A. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein. Journal of Virology 2001; 75:9644-9653.
4. Demirov DG, Orenstein JM & Freed EO. The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. Journal of Virology 2002; 76:105-117.
5. Dettenhofer M & Yu XF. Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins. Journal of Virology 1999; 73:4696-4704.
6. Göttlinger HG, Dorfman T, Sodroski JG & Haseltine WA. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proceedings of the National Academy of Sciences, USA 1991; 88:3195-3199.
7. Yu XF, Dawson L, Tian CJ, Flexner C & Dettenhofer M. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly. Journal of Virology 1998; 72:3412-3417.
8. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Cote M, Rich RL, Myszka DG & Sundquist WI. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001; 107:55-65.
9. Martin-Serrano J, Zang T & Bieniasz PD. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nature Medicine 2001; 7:1313-1319.
10. VerPlank L, Bouamr F, LaGrassa, TJ, Agresta B, Kikonyogo A, Leis J & Carter CA. Tsg 101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proceedings of the National Academy of Sciences, USA 2001; 98:7724-7729.
11. Kaufmann GR, Suzuki K, Cunningham P, Mukaide M, Kondo M, Imai M, Zaunders J & Cooper DA. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Research & Human Retroviruses 2001; 17:487-497.
12. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV & Montaner JS. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. Journal of the American Medical Association 2001; 286:2568-2577.
13. Alexander CS, Dong W, Chan K, Jahnke N, O'Shaughnessy MV, Mo T, Piaseczny MA, Montaner JS & Harrigan PR. HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS 2001; 15:601-607.
14. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS & Montaner JS. Adherence to triple therapy and viral load response. Journal of Acquired Immune Deficiency Syndrome 2000; 23:360-361.
15. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, Miedema F & Schuitemaker H. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. Journal of Virology 1992; 66:3183-3187.
16. Fouchier RA, Brouwer M, Broersen SM & Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. Journal of Clinical Microbiology 1995; 33:906-911.
17. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW & Richman DD. Drug resistance mutations in HIV-1. Topics in HIV Medicine 2002; 10:21-25.
18. Gallego O, De Mendoza C, Corral Z & Soriano V. Changes at the HIV-1 p6 protein among antiretroviralnaive and pre-treated patients. 42nd Interscience Conference on Antimicrobial Agents & Chomotherapy, San Diego, Calif., USA, September 27-30, 2002. Abstract H-2053.
19. Smith D, Little SJ, Daar ES, Koup R, Hellmann NS, Dawson K, Wong JK, Richman DD & Leigh Brown AJ. Genetic variation in p6gag in primary HIV infection. 9th Conference on Retroviruses & Opportunistic Infections, Seattle, Wash., USA, February 24-28, 2002. Abstract 357-M.
20. Bjorndal A, Deng H, Jansson M, Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR & Fenyo EM. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. Journal of Virology 1997; 71:7478-7487.
21. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, Miedema F, Schellekens PT & Tersmette M. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Annals of Internal Medicine 1993; 118:681-688.
22. Spijkerman I, de Wolf F, Langendam M, Schuitemaker H & Coutinho R. Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. Journal of Infectious Diseases 1998; 2:397-403.